OneMedNet Corp (NASDAQ: ONMD)

OneMedNet Corp, often recognized by its ticker symbol ONMD, operates in the Life Sciences industry, specializing in clinical imaging innovation and curation of regulatory-grade Imaging Real-World Data (iRWDTM). The company's primary business activities revolve around providing innovative solutions that connect healthcare providers and patients, offering direct access to clinical images and the associated contextual patient record. OneMedNet's operations span various countries and regions, contributing significantly to the global Life Sciences sector.

The company generates revenue primarily through the provision of its main products and services, with the iRWDTM offering being a significant segment. This service provides regulatory-grade image-centric data that aligns precisely with its Life Science partners' Case Selection Protocols. This data is highly curated and de-identified, ensuring its readiness for use by Life Science companies. The iRWDTM offering is designed to support Life Science product development, validation, and regulatory approval processes, thereby contributing to advancements in patient care.

OneMedNet's competitive advantage lies in its combination of advanced technology, clinical expert curation, and service. The company's data is fully de-identified using a multi-step quality control process that goes beyond Protected Health Information (PHI) to include Personally Identifiable Information (PII), Site Identifiable Information (SII), and more. This ensures the data's security and privacy, meeting the highest level of professional and ethical standards.

Life Science companies, including pharmaceutical companies, artificial intelligence (AI) developers, medical device businesses, and clinical research organizations, constitute OneMedNet's customer base. These customers rely on OneMedNet's products and services to support Life Science product development, validation, and regulatory approval processes.

The Life Sciences industry faces significant challenges, including the high cost of bringing a drug to market. Real-World Data (RWD) and Real-World Evidence (RWE) have emerged as powerful tools, providing valuable insights into patient health status and the delivery of healthcare. RWD is observational data collected from various sources, while RWE is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD.

AI is increasingly being used in RWD to enhance data anomaly detection, standardization, and quality checking at the pre-processing stage. AI innovations can also enhance drug development, improve patient treatment and access, and drive valuable new business opportunities. RWE is used by different stakeholders in various ways, including providing insight into how drugs are being used, helping providers improve the delivery of care, enabling regulatory authorities to monitor post-market safety and adverse events, and helping payers assess outcomes from treatments.

OneMedNet Corp, with its iRWDTM offering, is a leader in the business of extracting, securing, and transferring medical data. Its unique combination of knowledge, tools, and experience positions it well to continue providing innovative solutions that unlock the value in imaging archives and support patient care advancements. With the increasing importance of RWD and RWE in the Life Sciences industry, OneMedNet is well-positioned to maintain its strong industry position.